CSL LTD SPON.ADR 2 Total Liabilities
CSL LTD SPON.ADR 2 total liabilities. Based on the latest financial reports, CSL LTD SPON.ADR 2 (CSJA) has total liabilities worth €17.90 Billion EUR (≈ $20.93 Billion USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See CSL LTD SPON.ADR 2 (CSJA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of CSL LTD SPON.ADR 2 (2022–2025)
Total liabilities of CSL LTD SPON.ADR 2 from 2022 to 2025. This chart illustrates how CSL LTD SPON.ADR 2's total liabilities have evolved over time, based on quarterly financial data. See CSL LTD SPON.ADR 2 net asset quality index to measure how much of total assets are equity-financed.
CSL LTD SPON.ADR 2 Competitors by Total Liabilities
The table below lists competitors of CSL LTD SPON.ADR 2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Block, Inc
NYSE:XYZ
|
USA | $18.31 Billion |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
USA | $1.83 Billion |
|
Ameriprise Financial Inc
NYSE:AMP
|
USA | $178.24 Billion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $1.72 Billion |
|
JD.com Inc Adr
NASDAQ:JD
|
USA | $443.19 Billion |
|
Power Corporation Of Canada
TO:POW
|
Canada | CA$972.84 Billion |
|
Eoptolink Technology Inc Ltd
SHE:300502
|
China | CN¥12.18 Billion |
|
Fujikura Ltd
NYSE:FJIKY
|
USA | $376.26 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down CSL LTD SPON.ADR 2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CSL LTD SPON.ADR 2 balance sheet assets.
Liquidity & Leverage Metrics
CSL LTD SPON.ADR 2 Total Liabilities Ratios Explained
CSL LTD SPON.ADR 2 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CSL LTD SPON.ADR 2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CSL LTD SPON.ADR 2 (2022–2025)
The table below shows the annual total liabilities of CSL LTD SPON.ADR 2 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €18.00 Billion ≈ $21.04 Billion |
-3.35% |
| 2024-06-30 | €18.62 Billion ≈ $21.77 Billion |
+1.16% |
| 2023-06-30 | €18.41 Billion ≈ $21.52 Billion |
+33.70% |
| 2022-06-30 | €13.77 Billion ≈ $16.10 Billion |
-- |
About CSL LTD SPON.ADR 2
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more